Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  vismodegib
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-15 of 15 for your search:
Start Over
Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MEVITEM, 2011-003372-37, NCT01601184
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: J1013, NA_00036883, NCT01088815
Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: ML28485, NCT01700049
Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 to 18
Sponsor: Other
Protocol IDs: NMTRCPG007, NCT01774253
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC#122011, NCT01835626
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 to 21 at diagnosis
Sponsor: Other
Protocol IDs: SJMB12, NCI-2013-01125, NCT01878617
Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: Over 18
Sponsor: Other
Protocol IDs: Ribavirin=005, NCT02073838
A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf, and Erivedge Treatment Targeted Against Certain Mutations in Cancer Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML28897, NCT02091141
A Synthetic Hedgehog Pathway Inhibitor for Keratocystic Odontogenic Tumors (KCOT)
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: ML28859, NCT02366312
An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)
Phase: No phase specified
Type: Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML28296, NCT01604252
Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012-003516-31, NCT01713218
Levocarnitine in Treating Patients With Vismodegib-Associated Muscle Spasms
Phase: No phase specified
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: SKIN0018, NCI-2013-01269, 27478, P30CA124435, NCT01893892
A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: J1423, NA_00093427, NCT02115828
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-versus-Host Disease
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Supportive care
Status: Approved-not yet active
Age: 13 and over
Sponsor: NCI
Protocol IDs: NCI-2014-02672, 9664, P30CA046592, NCT02337517
An Observational Study of the Effectiveness and Safety of Erivedge® in Patients With Advanced Basal Cell Carcinoma
Phase: No phase specified
Type: Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML29507, NCT02371967
Start Over